Page last updated: 2024-11-04

oxaloacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxaloacetic acid : An oxodicarboxylic acid that is succinic acid bearing a single oxo group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID970
CHEMBL ID1794791
CHEBI ID30744
SCHEMBL ID8464
MeSH IDM0329072

Synonyms (75)

Synonym
EN300-28603
3-carboxy-3-oxopropanoic acid
CHEBI:30744 ,
OAA ,
oxosuccinic acid
butanedioic acid, oxo-
ketosuccinic acid
2-ketosuccinic acid
nsc-77688
nsc77688
butanedioic acid, oxo- (9ci)
oxalacetic acid (8ci)
oxaloethanoic acid
oxobutanedioic acid
alpha-ketosuccinic acid
oxaloacetic acid
2-oxosuccinic acid
oxaloacetate
2-oxobutanedioic acid
328-42-7
C00036
oxalacetic acid
oxaloacetic acid, powder, bioreagent, suitable for cell culture, suitable for insect cell culture, >=97% (hplc)
oxaloacetic acid, hybri-max(tm), powder, suitable for hybridoma
oxaloacetic acid, >=97% (hplc)
4CTS
nsc 77688
einecs 206-329-8
bdbm23230
O-5000
F15D7D2F-5E37-4B87-A8D2-824D5097A4DE
O0072
2-oxo-butanedioic acid
LMFA01170120
AKOS000121850
NCGC00248960-01
oxalacetic acetic
butanedioic acid, 2-oxo-
unii-2f399mm81j
2f399mm81j ,
dtxcid901646
cas-328-42-7
dtxsid8021646 ,
tox21_201215
NCGC00258767-01
STL168038
FT-0631962
S6112
gtpl5236
SCHEMBL8464
anhydrous enol-oxaloacetate
oxosuccinic acid [inci]
bioepg
oxalacetic acid trans-(z)-enol form [mi]
oxalacetic acid [who-dd]
oxalacetic acid [mi]
J-650320
J-650383
CHEMBL1794791
mfcd00002592
a-ketosuccinate
ketosuccinate
a-ketosuccinic acid
oxaloethanoate
alpha-ketosuccinate
2-ketosuccinate
2-oxosuccinate
BCP16299
Q408658
HY-W010382
AS-17361
H12016
CS-W011098
A875503
Z271128590

Research Excerpts

Overview

Oxaloacetic acid is an important intermediary in the tricarboxylic acid cycle (TCA cycle) and participates in metabolism and energy production.

ExcerptReferenceRelevance
"Oxaloacetic acid is an important intermediary in the tricarboxylic acid cycle (TCA cycle) and participates in metabolism and energy production."( Oxaloacetate Ameliorates Chemical Liver Injury via Oxidative Stress Reduction and Enhancement of Bioenergetic Fluxes.
Han, X; Kuang, Y; Wang, Y; Xu, M; Yang, Q; Zhao, Y, 2018
)
1.2

Toxicity

ExcerptReferenceRelevance
" More importantly, these findings suggest that blood glutamate grabbers are a safe treatment modality that can be given in cases of suspected ischemic stroke without previous neuroimaging."( Blood glutamate grabbing does not reduce the hematoma in an intracerebral hemorrhage model but it is a safe excitotoxic treatment modality.
Argibay, B; Campos, F; Castillo, J; da Silva-Candal, A; Gutiérrez-Fernández, M; Mirelman, D; Rey, RI; Rodríguez-Frutos, B; Sobrino, T; Vieites-Prado, A, 2015
)
0.42
"Both doses were safe and tolerated."( Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.
Anderson, H; Becker, A; Bothwell, R; Brooks, W; Burns, JM; Choi, IY; Clutton, J; Harris, RA; Lee, P; Mahnken, JD; Mosconi, L; Pleen, J; Reed, G; Sherry, E; Swerdlow, RH; Vidoni, ED; Wilkins, HM; Zhang, N, 2021
)
0.62
"1000 mg OAA, taken twice daily for 1 month, is safe in AD patients and engages brain energy metabolism."( Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.
Anderson, H; Becker, A; Bothwell, R; Brooks, W; Burns, JM; Choi, IY; Clutton, J; Harris, RA; Lee, P; Mahnken, JD; Mosconi, L; Pleen, J; Reed, G; Sherry, E; Swerdlow, RH; Vidoni, ED; Wilkins, HM; Zhang, N, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" We found that inhibition of the adenosine A2A receptor (A2AR) after brain injury alleviated the TBI-ALI; however, it is unknown whether lowering blood glutamate levels in combination with inhibiting the A2AR would lead to better effects."( Reduction in Blood Glutamate Levels Combined With the Genetic Inactivation of A2AR Significantly Alleviate Traumatic Brain Injury-Induced Acute Lung Injury.
Bai, W; Chen, X; Jiang, YL; Li, P; Ning, YL; Yang, N; Zhou, YG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Here, we examine the use of higher dosage AEO as a medical food to relieve pathological fatigue."( Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.
Cash, A; Kaufman, DL, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
oxo dicarboxylic acidAny dicarboxylic acid carrying one or more oxo groups.
C4-dicarboxylic acidAny dicarboxylic acid that contains four carbon atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (128)

PathwayProteinsCompounds
Amino acid synthesis and interconversion (transamination)2343
Alanine Metabolism513
Citric Acid Cycle2127
Urea Cycle1325
Aspartate Metabolism1430
Arginine and Proline Metabolism2047
Glutamate Metabolism2244
Pyruvate Metabolism2139
Malate-Aspartate Shuttle48
Gluconeogenesis2232
Tyrosine Metabolism1657
Primary Hyperoxaluria Type I513
Pyruvate Carboxylase Deficiency513
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Prolidase Deficiency (PD)2047
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)2047
Hyperprolinemia Type II2047
Hyperprolinemia Type I2047
Prolinemia Type II2047
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)2047
Ornithine Aminotransferase Deficiency (OAT Deficiency)2047
Canavan Disease1430
Hypoacetylaspartia1430
Lactic Acidemia513
Leigh Syndrome2139
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)2139
Pyruvate Dehydrogenase Complex Deficiency2139
Transfer of Acetyl Groups into Mitochondria919
Alkaptonuria1657
Hawkinsinuria1657
Tyrosinemia Type I1657
Argininemia1325
Argininosuccinic Aciduria1325
Citrullinemia Type I1325
Ornithine Transcarbamylase Deficiency (OTC Deficiency)1325
Carbamoyl Phosphate Synthetase Deficiency1325
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
2-Hydroxyglutric Aciduria (D and L Form)2244
Disulfiram Action Pathway2366
Tyrosinemia, Transient, of the Newborn1657
Dopamine beta-Hydroxylase Deficiency1657
Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency2047
Hyperornithinemia with Gyrate Atrophy (HOGA)2047
Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]2047
L-Arginine:Glycine Amidinotransferase Deficiency2047
Monoamine Oxidase-A Deficiency (MAO-A)1657
Congenital Lactic Acidosis2127
Fumarase Deficiency2127
Mitochondrial Complex II Deficiency2127
2-Ketoglutarate Dehydrogenase Complex Deficiency2127
Pyruvate Dehydrogenase Deficiency (E3)2127
Pyruvate Dehydrogenase Deficiency (E2)2127
Primary Hyperoxaluria II, PH22139
Pyruvate Kinase Deficiency2139
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Succinic Semialdehyde Dehydrogenase Deficiency2244
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
TCA Cycle1825
L-Glutamate Metabolism2420
Asparagine Biosynthesis612
Threonine Biosynthesis1123
Gluconeogenesis from L-Malic Acid2024
Secondary Metabolites: Glyoxylate Cycle715
TCA cycle (ubiquinol-2)1824
TCA cycle (ubiquinol-3)1823
TCA cycle (ubiquinol-4)1824
TCA cycle (ubiquinol-5)1823
TCA cycle (ubiquinol-6)1825
TCA cycle (ubiquinol-7)1825
TCA cycle (ubiquinol-8)1825
TCA cycle (ubiquinol-9)1823
TCA cycle (ubiquinol-10)1824
Glycolate and Glyoxylate Degradation II1221
TCA cycle (ubiquinol-0)1825
Asparagine Metabolism412
The Oncogenic Action of 2-Hydroxyglutarate2734
The Oncogenic Action of Succinate2933
The Oncogenic Action of Fumarate2934
Glutaminolysis and Cancer3536
Glyoxylate Cycle613
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Glutamine Metabolism2225
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
2-Oxo-glutaric acid + L-Aspartic acid = L-Glutamic acid + Oxaloacetic acid ( Alanine,Aspartic acid and Asparagine metabolism )24
ATP + Pyruvic acid + CO2 + H2O = ADP + Oxaloacetic acid + Orthophosphate ( Alanine,Aspartic acid and Asparagine metabolism )17
Citrate cycle ( Citrate cycle )2129
NAD+ + (S)-Malic acid = NADH + Oxaloacetic acid ( Citrate cycle )24
GTP + Oxaloacetic acid = GDP + Phosphoenol-pyruvic acid + CO2 ( Citrate cycle )25
ATP + Pyruvic acid + CO2 + H2O = ADP + Oxaloacetic acid + Orthophosphate ( Glycolysis and Gluconeogenesis )17
ATP + CoA + Citric acid = ADP + Acetyl-CoA + Oxaloacetic acid + Orthophosphate ( Lysine degradation )17
Amino acid metabolism pathway excerpt: histidine catabolism extension016
Ketogenesis and ketolysis89
Citrate Cycle1930
TCA Cycle (Ubiquinol-2)424
TCA Cycle (Ubiquinol-3)423
TCA Cycle (Ubiquinol-4)424
TCA Cycle (Ubiquinol-5)423
TCA Cycle (Ubiquinol-6)425
TCA Cycle (Ubiquinol-7)425
TCA Cycle (Ubiquinol-8)425
TCA Cycle (Ubiquinol-9)423
TCA Cycle (Ubiquinol-10)424
TCA Cycle (Ubiquinol-0)425
TCA cycle in senescence011
Amino acid metabolism in triple-negative breast cancer cells016
Metabolic reprogramming in pancreatic cancer4223
TCA cycle (plant)121
Metabolic Epileptic Disorders2589
TCA cycle, aerobic respiration020
glutamine degradation07
Carbon assimilation C4 pathway030
Central carbon metabolism019
TCA cycle010
Hexoses metabolism in proximal tubules016
Gluconeogenesis012
Principal pathways of carbon metabolism07
Aspartate biosynthesis03
Primary carbon metabolism2330
Krebs cycle110
TCA cycle (Krebs cycle)3019
AtMetExpress overview0109
Alanine and aspartate metabolism015
TCA cycle and deficiency of pyruvate dehydrogenase complex (PDHc)015
Fatty acid biosynthesis03
Metabolism overview078
Biochemical pathways: part I0466
Amino acid metabolism094
Metabolic reprogramming in colon cancer029
Thiamine metabolic pathways116
Glycolysis and gluconeogenesis017
TCA cycle (aka Krebs or citric acid cycle)024
Effect of L-carnitine on metabolism09

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency54.64890.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency34.09410.000221.22318,912.5098AID1259243; AID1259247; AID1259381
progesterone receptorHomo sapiens (human)Potency77.19370.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.31710.003041.611522,387.1992AID1159552
pregnane X nuclear receptorHomo sapiens (human)Potency48.70590.005428.02631,258.9301AID1346982
histone deacetylase 9 isoform 3Homo sapiens (human)Potency34.48110.037617.082361.1927AID1259364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prolyl 4-hydroxylaseParamecium bursaria Chlorella virus 1IC50 (µMol)1,000.00005.00006.26678.5000AID1543452
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CITRATE SYNTHASESus scrofa (pig)Kd10.000010.000010.000010.0000AID977611
Chain B, CITRATE SYNTHASESus scrofa (pig)Kd10.000010.000010.000010.0000AID977611
Methyl-accepting chemotaxis protein NahYPseudomonas putidaKd23.90008.50008.50008.5000AID1799787
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
nucleoside diphosphate kinase activityPhosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolPhosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1802647PEPCK Inhibition Assay from Article 10.1021/acs.biochem.7b00178: \\Asymmetric Anchoring Is Required for Efficient O-Loop Opening and Closing in Cytosolic Phosphoenolpyruvate Carboxykinase.\\2017Biochemistry, 04-18, Volume: 56, Issue:15
Asymmetric Anchoring Is Required for Efficient Ω-Loop Opening and Closing in Cytosolic Phosphoenolpyruvate Carboxykinase.
AID1799787Isothermal Titration Calorimetry from Article 10.1074/jbc.M110.110403: \\Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: differential chemotactic response towards receptor ligands.\\2010The Journal of biological chemistry, Jul-23, Volume: 285, Issue:30
Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: differential chemotactic response towards receptor ligands.
AID1824728Inhibition of pyruvate carboxylase in human HepG2 cells measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824729Inhibition of pyruvate carboxylase in human HCCLM3 cells measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1543452Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Inhibition of a viral prolyl hydroxylase.
AID681001TP_TRANSPORTER: inhibition of Glutarate uptake (Glutarate: 5 uM, Oxaloacetate: 1000 uM) in Xenopus laevis oocytes2002Molecular pharmacology, Jul, Volume: 62, Issue:1
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
AID1824731Inhibition of pyruvate carboxylase in human HCCLM3 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824730Inhibition of pyruvate carboxylase in human HepG2 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1984Journal of molecular biology, Mar-25, Volume: 174, Issue:1
Crystal structure analysis and molecular model of a complex of citrate synthase with oxaloacetate and S-acetonyl-coenzyme A.
AID1811Experimentally measured binding affinity data derived from PDB1984Journal of molecular biology, Mar-25, Volume: 174, Issue:1
Crystal structure analysis and molecular model of a complex of citrate synthase with oxaloacetate and S-acetonyl-coenzyme A.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (416)

TimeframeStudies, This Drug (%)All Drugs %
pre-199088 (21.15)18.7374
1990's15 (3.61)18.2507
2000's124 (29.81)29.6817
2010's152 (36.54)24.3611
2020's37 (8.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.54 (24.57)
Research Supply Index6.08 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index130.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.46%)5.53%
Reviews16 (3.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other416 (95.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]